2nd Quarter - Report

WILLIAMS AND JENSEN, PLLC for PFIZER

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Tax issues affecting the pharmaceutical industry

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Labor Issues/Antitrust/Workplace LBR

Wyeth acquisition

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
ANTHONY J RODA New Leadership Staff, House Whip Gingrich

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.

LobbyistCovered position, as disclosed
JENNY DIJAMES —
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN —
KARINA LYNCH —
MELINDA M MAXFIELD —
GEORGE OLSEN —
JOYCE A ROGERS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1725 (111th), S. 547 (111th), H.R. 904 (111th), S. 266 (111th), S. 330 (111th), H.R. 684 (111th)

Health Issues HCR

Drug safety and drug counterfeiting; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Health care reform including the Affordable Health Choices Act; Senator Kennedy cancer legislation; Prescription drug advertising; and Federal preemption for prescription drugs.

LobbyistCovered position, as disclosed
REBECCA ANDERSON New White House Office of Legislative Affairs
JENNY DIJAMES —
JACK STEVEN HART —
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN —
KARINA LYNCH —
MELINDA M MAXFIELD —
GEORGE OLSEN —
PATRICK PETTEY New COS, Rep. Robert Smith & Sen. Robert Smith
ANTHONY J RODA New Leadership Staff, House Whip Gingrich
JOYCE A ROGERS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 301 (111th), H.R. 1 (111th), H.R. 1298 (111th), S. 1232 (111th), S. 1213 (111th), H.R. 1548 (111th), S. 726 (111th), S. 525 (111th), H.R. 1427 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.